CareDx, Inc. (CDNA)
NASDAQ: CDNA · Real-Time Price · USD
18.75
-0.31 (-1.63%)
Mar 5, 2026, 4:00 PM EST - Market closed
CareDx Revenue
In the year 2025, CareDx had annual revenue of $379.81M with 13.79% growth. CareDx had revenue of $108.39M in the quarter ending December 31, 2025, with 25.19% growth.
Revenue (ttm)
$379.81M
Revenue Growth
+13.79%
P/S Ratio
2.53
Revenue / Employee
$496,477
Employees
765
Market Cap
960.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 379.81M | 46.02M | 13.79% |
| Dec 31, 2024 | 333.79M | 53.46M | 19.07% |
| Dec 31, 2023 | 280.32M | -41.47M | -12.89% |
| Dec 31, 2022 | 321.79M | 25.40M | 8.57% |
| Dec 31, 2021 | 296.40M | 104.20M | 54.22% |
| Dec 31, 2020 | 192.19M | 65.13M | 51.25% |
| Dec 31, 2019 | 127.07M | 50.50M | 65.95% |
| Dec 31, 2018 | 76.57M | 28.25M | 58.45% |
| Dec 31, 2017 | 48.32M | 7.69M | 18.93% |
| Dec 31, 2016 | 40.63M | 12.49M | 44.37% |
| Dec 31, 2015 | 28.14M | 838.00K | 3.07% |
| Dec 31, 2014 | 27.31M | 5.21M | 23.57% |
| Dec 31, 2013 | 22.10M | 1.65M | 8.05% |
| Dec 31, 2012 | 20.45M | 17.51M | 595.14% |
| Dec 31, 2006 | 2.94M | 2.62M | 799.69% |
| Dec 31, 2005 | 327.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neogen | 880.32M |
| Myriad Genetics | 824.50M |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| Twist Bioscience | 391.56M |
| Castle Biosciences | 344.23M |
CDNA News
- 6 hours ago - CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets - Business Wire
- 6 days ago - CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer - Business Wire
- 9 days ago - CareDx Announces Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 15 days ago - CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference - Business Wire
- 18 days ago - Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells - Seeking Alpha
- 21 days ago - CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript - Seeking Alpha